Olpasiran
O'Donoghue ML, G López JA, Knusel B, et al. Study design and rationale for the Olpasiran trials of Cardiovascular Events And lipoproteiN(a) reduction-DOSE finding study (OCEAN(a)-DOSE). Am Heart J. 2022;251:61-69. doi:10.1016/j.ahj.2022.05.004Olpasiran (AMG890) is an experimental siRNA (short interfering RNA) therapy designed to lower the level of lipoprotein(a), which is believed to be a causal factor in the development of cardiovascular disease. The drug is developed by Amgen.{{cite journal |last1=O’Donoghue |first1=Michelle L. |last2=Rosenson |first2=Robert S. |last3=Gencer |first3=Baris |last4=López |first4=J. Antonio G. |last5=Lepor |first5=Norman E. |last6=Baum |first6=Seth J. |last7=Stout |first7=Elmer |last8=Gaudet |first8=Daniel |last9=Knusel |first9=Beat |last10=Kuder |first10=Julia F. |last11=Ran |first11=Xinhui |last12=Murphy |first12=Sabina A. |last13=Wang |first13=Huei |last14=Wu |first14=You |last15=Kassahun |first15=Helina |last16=Sabatine |first16=Marc S. |author-link2=Robert S. Rosenson |title=Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease |journal=New England Journal of Medicine |date=17 November 2022 |volume=387 |issue=20 |pages=1855–1864 |doi=10.1056/NEJMoa2211023|doi-access=free |pmid=36342163 }}{{cite journal |last1=Koren |first1=Michael J. |last2=Moriarty |first2=Patrick Maurice |last3=Baum |first3=Seth J. |last4=Neutel |first4=Joel |last5=Hernandez-Illas |first5=Martha |last6=Weintraub |first6=Howard S. |last7=Florio |first7=Monica |last8=Kassahun |first8=Helina |last9=Melquist |first9=Stacey |last10=Varrieur |first10=Tracy |last11=Haldar |first11=Saptarsi M. |last12=Sohn |first12=Winnie |last13=Wang |first13=Huei |last14=Elliott-Davey |first14=Mary |last15=Rock |first15=Brooke M. |last16=Pei |first16=Tao |last17=Homann |first17=Oliver |last18=Hellawell |first18=Jennifer |last19=Watts |first19=Gerald F. |title=Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a) |journal=Nature Medicine |date=January 2022 |volume=28 |issue=1 |pages=96–103 |doi=10.1038/s41591-021-01634-w |pmid=35027752 |url=https://www.nature.com/articles/s41591-021-01634-w |language=en |issn=1546-170X|url-access=subscription }}